Edward Jung, MD
Radiation Oncology · West Covina, CANPI 1003011941
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.7%), consulting fees and education — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by AstraZeneca at 49.4% of the total. Reporting peaked in 2024 at $2,286 and has fallen 95.1% since, to $112 in 2025.
Across 107 payments — averaging $43.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Genentech USA, Inc.$331
- Novocure Inc.$228
- Elekta, Inc.$203
- E.r. Squibb & Sons, L.L.C.$165
- Amgen$154
- plus $1K from 27 others
What the payments were for
- Consulting fees$2,10045%
- Food & beverage$2,44153%
- Education$882%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 15 | $2,287 |
| Genentech USA, Inc. | 10 | $331 |
| Novocure Inc. | 5 | $228 |
| Elekta, Inc. | 4 | $203 |
| E.r. Squibb & Sons, L.L.C. | 16 | $165 |
| Amgen | 7 | $154 |
| Siemens Medical Solutions USA, Inc. | 1 | $117 |
| Aimmune Therapeutics, Inc. | 1 | $112 |
| Intuitive Surgical | 1 | $98 |
| Johnson & Johnson(2 entities) | 6 | $87 |
| Boston Scientific | 3 | $86 |
| AbbVie | 4 | $82 |
| Tesaro, Inc. | 4 | $82 |
| Sumitomo Pharma America, Inc. | 3 | $73 |
| Incyte Corporation | 3 | $52 |
| Seagen Inc. | 2 | $48 |
| Regeneron Healthcare Solutions, Inc. | 1 | $37 |
| Myriad Genetic Laboratories, Inc. | 2 | $36 |
| Bayer | 2 | $33 |
| Pfizer | 2 | $32 |
| Merck | 1 | $29 |
| Dendreon Pharmaceuticals LLC | 1 | $29 |
| Eisai Inc. | 2 | $28 |
| Progenics Pharmaceuticals, Inc. | 1 | $28 |
| Boehringer Ingelheim | 2 | $28 |
| Myovant Sciences Inc. | 1 | $24 |
| GSK | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Tactile Systems Technology Inc | 1 | $17 |
| Blue Earth Diagnostics | 1 | $17 |
| Exelixis Inc. | 1 | $16 |
| EUSA Pharma (US) LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$1,575
- TAGRISSO$525
- Oncology$149
- Bravos Afterloader System$117
- ZENPEP$112
How this compares
$4,629 in reported general payments places this provider in the 80th percentile of 627 radiation oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other radiation oncology in West Covina
- Rakesh PatelLos Gatos$1.3M
- Amir LavafPalm Springs$411K
- Albert ChangLos Angeles$290K
- Arya AminiDuarte$265K
- Rizwan NuraniApple Valley$220K
- Drew MoghanakiLos Angeles$183K
- Jyoti MayadevSan Diego$170K
- Percy LeeIrvine$125K
- Felix FengSan Francisco$99K
- Hyun KimDuarte$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.